DK3131874T3 - Hidtil ukendte cannabidiolquinonderivater - Google Patents

Hidtil ukendte cannabidiolquinonderivater Download PDF

Info

Publication number
DK3131874T3
DK3131874T3 DK14723345.6T DK14723345T DK3131874T3 DK 3131874 T3 DK3131874 T3 DK 3131874T3 DK 14723345 T DK14723345 T DK 14723345T DK 3131874 T3 DK3131874 T3 DK 3131874T3
Authority
DK
Denmark
Prior art keywords
compound
pparg
compounds
cells
methyl
Prior art date
Application number
DK14723345.6T
Other languages
English (en)
Inventor
Giovanni Appendino
Blanco Eduardo Muñoz
Cabello De Alba María Luz Bellido
Original Assignee
Emerald Health Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emerald Health Pharmaceuticals Inc filed Critical Emerald Health Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3131874T3 publication Critical patent/DK3131874T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/28—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of non-condensed quinone rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/95—Esters of quinone carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (10)

  1. HIDTIL UKENDTE CANNABIDIOLQUINONDERIVATER
    1. Forbindelser med formlen (I)
    hvor R er carbonatomet af en lineær eller forgrenet gruppe, der er repræsenteret ved: aryl-, alkenyl-, alkynyl-, acyl- eller alkoxycarbonylgrupper; eller hvor R er nitrogenatomet af en lineær eller forgrenet gruppe, der er repræsenteret ved: alkylamin-, arylamin-, alkenylamin- eller alkynylamingrupper.
  2. 2. Forbindelse ifølge krav 1 valgt fra:
  3. 3. Sammensætninger, der omfatter en forbindelse med formlen (I)
    hvor R er carbonatomet af en lineær eller forgrenet gruppe, der er repræsenteret ved: aryl-, alkenyl-, alkynyl-, acyl- eller alkoxycarbonylgrupper; eller hvor R er nitrogenatomet af en lineær eller forgrenet gruppe, der er repræsenteret ved: alkylamin-, arylamin-, alkenylamin- eller alkynylamingrupper, og, eventuelt, mindst en yderligere aktiv forbindelse og/eller mindst en farmaceutisk inert bestanddel, såsom en excipiens og/eller bærer.
  4. 4. Sammensætning ifølge krav 3, hvor forbindelsen med formlen (I) er valgt fra:
    (XV)
  5. 5. Forbindelse, ifølge et hvilket som helst af kravene 1 eller 2 til anvendelse som lægemiddel.
  6. 6. Forbindelse, ifølge et hvilket som helst af kravene 1 eller 2 til anvendelse i behandlingen af PPARg-medierede sygdomme.
  7. 7. Forbindelse til anvendelse ifølge krav 6 i behandlingen af en PPARg-medieret sygdom valgt fra: aterosklerose, inflammatoriske tarmsygdomme, rheumatoid arthritis, leverfibrose, nefropati, psoriasis, heling af hudsår, hudregeneration, pancreatitis, gastritis, neurodegenerative forstyrrelser, neuroinflammatoriske forstyrrelser, sklerodermi, cancer, hypertension, fedme eller type II diabetes.
  8. 8. Sammensætning ifølge et hvilket som helst af kravene 3 eller 4 til anvendelse som lægemiddel.
  9. 9. Sammensætning ifølge et hvilket som helst af kravene 3 eller 4 til anvendelse i behandlingen af PPARg-medierede sygdomme.
  10. 10. Sammensætning til anvendelse ifølge krav 9 i behandlingen af en PPARg-medieret sygdom valgt fra: aterosklerose, inflammatoriske tarmsygdomme, rheumatoid arthritis, leverfibrose, nefropati, psoriasis, heling af hudsår, hudregeneration, pancreatitis, gastritis, neurodegenerative forstyrrelser, neuroinflammatoriske forstyrrelser, sklerodermi, cancer, hypertension, fedme eller type II diabetes.
DK14723345.6T 2014-04-16 2014-04-16 Hidtil ukendte cannabidiolquinonderivater DK3131874T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/057767 WO2015158381A1 (en) 2014-04-16 2014-04-16 Novel cannabidiol quinone derivatives

Publications (1)

Publication Number Publication Date
DK3131874T3 true DK3131874T3 (da) 2018-11-19

Family

ID=50693623

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14723345.6T DK3131874T3 (da) 2014-04-16 2014-04-16 Hidtil ukendte cannabidiolquinonderivater

Country Status (14)

Country Link
US (1) US9701618B2 (da)
EP (1) EP3131874B1 (da)
JP (1) JP6167248B2 (da)
KR (1) KR102256398B1 (da)
CN (1) CN106232570B (da)
AU (1) AU2014390738B2 (da)
BR (1) BR112016023902A2 (da)
CA (1) CA2945867C (da)
DK (1) DK3131874T3 (da)
ES (1) ES2692693T3 (da)
IL (1) IL248030B (da)
MX (1) MX352386B (da)
RU (1) RU2667504C2 (da)
WO (1) WO2015158381A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3058352A1 (en) 2017-03-29 2018-10-04 Eduardo Munoz Blanco Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity
CN106866419B (zh) * 2017-04-14 2020-01-10 石河子大学 一类萜酯化合物及其制备方法和用途
WO2018235079A1 (en) * 2017-06-20 2018-12-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. CANNABIDIOLIC ACID ESTER COMPOSITIONS AND USES THEREOF
WO2020120637A1 (en) * 2018-12-11 2020-06-18 Emerald Health Pharmaceuticals Inc Cannabigerol quinone acid and salts thereof
WO2020163612A1 (en) * 2019-02-06 2020-08-13 Emerald Health Pharmaceuticals Inc. Formulations of cannabidiol derivatives and their use as modulators of cannabinoid receptor type 2 (cb2)
WO2021064730A1 (en) 2019-10-03 2021-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Liposomal cannabinoids and uses thereof
CN113087599A (zh) * 2020-01-08 2021-07-09 成都百裕制药股份有限公司 大麻二酚衍生物及其制备方法和在医药上的应用
US20230137092A1 (en) * 2020-02-06 2023-05-04 Emerald Health Pharmaceuticals Inc. Composition and Method for the Treatment and Prevention of Cardiac, Pulmonary, Dermal, and Renal Fibrosis
US20240041904A1 (en) * 2020-12-24 2024-02-08 Buzzelet Development And Technologies Ltd. Compositions comprising cannabinoid acid esters
CN114315585B (zh) * 2022-03-04 2022-05-13 中国医学科学院药用植物研究所 一种羟戊苯甲酸双酯化合物及其制备方法和制药应用
CN116407529B (zh) * 2023-03-24 2024-05-10 南京医科大学 3-硝基-2,6-二羟基苯甲酸右崁醇或葑醇的酯的药物用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL159892A0 (en) * 2004-01-15 2004-06-20 Yissum Res Dev Co Use of quinonoid derivatives of cannabinoids in the treatment of malignancies
US20090093521A1 (en) * 2005-06-14 2009-04-09 Maria Laura Bolognesi 2, 5-Bis-Diamine [1,4] Benzoquinone-Derivatives
EP2139847A1 (en) * 2007-03-05 2010-01-06 Yissum Research Development Company, of The Hebrew University of Jerusalem Novel quinonoid derivatives of cannabinoids and their use in the treatment of malignancies
US8772349B2 (en) * 2010-03-26 2014-07-08 Vivacell Biotechnology Espana, S.L. Cannabinoid quinone derivatives
US20130203715A1 (en) * 2010-07-20 2013-08-08 Pulmatrix, Inc. Use of trp channel agonists to treat infections

Also Published As

Publication number Publication date
IL248030B (en) 2019-10-31
CA2945867C (en) 2021-11-09
EP3131874B1 (en) 2018-07-25
CN106232570B (zh) 2018-08-07
CN106232570A (zh) 2016-12-14
MX2016013151A (es) 2017-02-02
RU2016137668A3 (da) 2018-05-16
MX352386B (es) 2017-11-22
EP3131874A1 (en) 2017-02-22
KR20160146765A (ko) 2016-12-21
US20170044092A1 (en) 2017-02-16
ES2692693T3 (es) 2018-12-04
IL248030A0 (en) 2016-11-30
RU2667504C2 (ru) 2018-09-21
CA2945867A1 (en) 2015-10-22
AU2014390738A1 (en) 2016-10-27
US9701618B2 (en) 2017-07-11
RU2016137668A (ru) 2018-05-16
JP6167248B2 (ja) 2017-07-19
WO2015158381A1 (en) 2015-10-22
AU2014390738B2 (en) 2019-05-02
BR112016023902A2 (pt) 2017-08-15
JP2017516753A (ja) 2017-06-22
KR102256398B1 (ko) 2021-05-27

Similar Documents

Publication Publication Date Title
DK3131874T3 (da) Hidtil ukendte cannabidiolquinonderivater
CA2584485C (en) Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
EP1218368B1 (en) COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING bcl-2 FAMILY MEMBER PROTEINS
Ferreira et al. Synthesis of 1, 3-thiazine-2, 4-diones with potential anticancer activity
Romagnoli et al. Design, synthesis and biological evaluation of novel vicinal diaryl-substituted 1H-Pyrazole analogues of combretastatin A-4 as highly potent tubulin polymerization inhibitors
CA2937275C (en) Novel cannabigerol derivatives
CA2874057A1 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
CA2910255A1 (en) Inhibitors of nicotinamide phosphoribosyltransferase, compositions, products and uses thereof
Mu et al. The potential role of the 5, 6-dihydropyridin-2 (1 H)-one unit of piperlongumine on the anticancer activity
WO2013148994A1 (en) Glucose transporter inhibitors
Liao et al. Design, synthesis and structure-activity relationship of dihydrobenzoquinolines as novel inhibitors against influenza A virus
Zha et al. Synthesis and in vitro anticancer evaluation of novel flavonoid-based amide derivatives as regulators of the PI3K/AKT signal pathway for TNBC treatment
RU2734253C2 (ru) Тиазолидиноновые соединения и их применение для лечения психических или неврологических нарушений и воспаления, в частности нейровоспаления
Liu et al. Synthesis of a celastrol derivative as a cancer stem cell inhibitor through regulation of the STAT3 pathway for treatment of ovarian cancer
Wang et al. Design and synthesis of salidroside analogs and their bioactivity against septic myocardial injury
CA3172149A1 (en) Selective non-cyclic nucleotide activators for the camp sensor epac1
KR100671243B1 (ko) 펜타플루오로벤젠설폰아미드및동족체